•Empire Forum co-chairs preview retina's new investor-industry meeting•Bausch + Lomb's oral dry AMD therapy advances to clinical evaluation •Glaukos reports positive 3-year, phase 3 Epioxa clinical outcomes•GLP-1 drugs increase risk for periorbital changes•SpyGlass Pharma unveils positive 12-month data on BIM-IOL System•Empire Forum co-chairs preview retina's new investor-industry meeting•Bausch + Lomb's oral dry AMD therapy advances to clinical evaluation •Glaukos reports positive 3-year, phase 3 Epioxa clinical outcomes•GLP-1 drugs increase risk for periorbital changes•SpyGlass Pharma unveils positive 12-month data on BIM-IOL System
HEADLINES
FEATURED
Subcutaneous version of satralizumab-mwge can be administered by a patient or caregiver following training from an HCP.
Earn FREE CE 24/7 with Courses by Eyes On Eyecare
Explore premium-quality, bite-sized courses featuring leading experts like Cecelia Koetting, OD, FAAO, and Cory Lappin, OD, MS, FAAO, and continuing education covering topics from ocular rosacea treatments to retinal disease.
